news.cision.com

· Ericsson and KDDI have signed a collaborative agreement for a 5G proof of concept test in several cities across Japan · The test activities will be based on the 4.5GHz frequency band, a candidate frequency band for 5G in Japan, and will be completed by March 2018 · The scope of the trial also covers interworking between LTE and 5G using 4.5GHz and 28GHz frequency bandsEricsson (NASDAQ: ERIC) and KDDI, a leading Japanese operator, have agreed to test a 5G proof of concept on the 4.5GHz frequency band in a number of cities across Japan. The 4.5GHz frequency band is one of the

ÅF introduces a new division structure and changes in Group Management as a result of the ongoing strategy review

“ÅF will continue to grow, become more international and make greater use of the knowledge we have within the company. We are now sharpening our division structure as an initial step in this effort,” says Jonas Gustavsson, President and CEO. ÅF has approximately 10,000 employees with a unique breadth of competences combining the infrastructure, industry and energy sectors with technology and digital solutions. Together with its customers, ÅF drives development within disruptive trends such as Smart Cities, Industrial Digitalization and Future of Mobility. During the spring, ÅF

Caverion to implement telematic and other technical systems for new Teollisuuskatu tunnel in Helsinki, Finland

Caverion Corporation Investor news, September 11, 2017 at 10.00 a.m. EESTCaverion to implement telematic and other technical systems for new Teollisuuskatu tunnel in Helsinki, Finland Caverion is delivering technical systems and a telematic system for managing traffic in the new Teollisuuskatu tunnel in Central Pasila in Helsinki, Finland. The delivery is valued at approximately EUR 5.4 million and the client is the City of Helsinki. Caverion's project execution for the tunnel, which measures approximately 430 metres in length, includes a telematic system and associated

ADDvise Group’s long term financial targets

The board of directors of ADDvise Group has adopted long term financial targets. The strategy to focus on high revenue growth based on a combination of acquisitions and organic growth remains. Profitable revenue growth combined with reduced net debt to EBITDA is an overall target. Given time dividend to ADDvise Group’s shareholders will be added. ADDvise Group’s long term financial targets is not to be mistaken for an annual forecast. The financial targets should be seen as an ambition from the board and CEO. The targets will be achieved both by acquisitions and organic growth. The

Höganästo deliver customised industrial wastewater solution to SKF Brazil

Mon, Sep 11, 2017 08:45 CET

Swedish metal powder company Höganäs achieves an important milestone as Cleanit® EC is chosen as the best alternative for industrial wastewater treatment at SKF Brazil. Decisive in SKF’s choice was high level of innovation and economic competitiveness.Höganäs Brazil and local partners developed a complete solution based on the patent pending electrocoagulation technology Cleanit® EC. The customised process was designed to reduce oil, grease and suspended solids and colloids in the wastewater from the bearing plant.* SKF Brazil’s primary interest was to upgrade its existing wastewater

Brighter draws down the second tranche under the financing agreement with L1 Capital and issues additional free warrants to its shareholders.

Brighter has called upon a second Tranche of SEK 10 million in line with the terms from the financing agreement communicated on the 26thof April 2017. The transaction is carried out through a private placement of convertible notes with warrants attached. It is the second tranche out of a total of up to 8 tranches totaling SEK 100 million. It is precised that SEK 29.7 million of Notes of the first Tranche out of the SEK 30 million have been converted into equity as of today, strengthening the company’s balance sheet. This investment as part of the agreement as such, serves as a great

Episurf Medical AB will exhibit at the London Knee Meeting held in London, UK, on October 3

Mon, Sep 11, 2017 08:35 CET

Episurf Medical (NASDAQ: EPIS B) will exhibit at the London Knee Meeting (recognized as one of the most important meetings in the orthopaedic calendar) held in London, UK (Queen Elizabeth II Conference Centre), on Tuesday October 3. For full program, see http://www.londonkneemeeting.co.uk/. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical

Eniro has received underwriting commitments for the cash issue and extends the acceptance period for the exchange offerings one last time

Mon, Sep 11, 2017 08:35 CET

Eniro has received underwriting commitments for the cash issue amounting to SEK 275 million and extends the acceptance period for the exchange offerings one last time This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition

Episurf Medical AB will exhibit at The Individualized TKA, held in Antwerp, Belgium, on September 22

Episurf Medical (NASDAQ: EPIS B) will exhibit at The Individualized TKA (a meeting organized by the Belgian and the Dutch Knee Society) held in Antwerp, Belgium (Elzenveld), on September 22. For full program see http://www.bvot.be/images/programma-uitnodiging.pdf. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences). For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is

Nuevolution to present at three investor conferences in September 2017

Stockholm, 11 September 2017 -- Nuevolution AB (publ) (NUE.ST), a leading small-molecule drug-discovery biotech company, today announced that it will be presenting at three investor conferences in the US, Sweden and Denmark in September. First, the company will present at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference will take place on 11-12 September 2017 at the Lotte New York Palace Hotel in New York City. Henrik D. Simonsen, CFO of Nuevolution AB (publ), will provide an overview of the Company’s business during the live presentation on 12 September

Net Gaming redeems existing bond loan

Net Gaming Europe AB (publ) has decided to redeem all outstanding senior secured bonds with ISIN SE000834221 (the "Bonds").Net Gaming Europe AB (publ) has decided to redeem all outstanding Bonds. The redemption will take place on 5 October 2017 with the applicable record date on 28 September 2017. The Bonds will, in connection with the redemption, be delisted from the corporate bond list of Nasdaq First North 26 September 2017. The redemption amount will be established on the redemption date. For further information please contact:Marcus Teilman, President and CEO+356 9936 7352

BillerudKorsnäs production unit in Karlsborg expected to be back to full production during next week

During the night between September 5th and 6th, there was a fire in one of the buildings at BillerudKorsnäs’ production unit in Karlsborg and the production has been stopped since then. After analysing the impact of the fire, BillerudKorsnäs now expects Karlsborg to be back to full production during the week starting with Monday September 18th."The most important thing is that no person has been injured in the fire. We have now assessed the impact of the fire and the work with making the unit ready for start of production is ongoing at high intensity. We expect full production to be reached

New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children

A randomized, double-blind, placebo-controlled intervention trial has evaluated the effect of probiotics from Probi in children genetically predisposed for gluten intolerance (Celiac Disease). The results show that the probiotics have a suppressing effect on celiac autoimmunity and may delay the onset of the disease. Celiac disease affects up to 3% of the population and currently the introduction of a lifelong gluten-free diet is the only available treatment. Consistent study results. The randomized, double-blind, placebo controlled intervention study was performed by Dr. Daniel Agardh (

Veidekke ASA: MANDATORY NOTIFICATION OF TRADE

Mon, Sep 11, 2017 08:13 CET

On 8 September 2017 Stiftelsen Veidekkeansattes aksjekjøp (the Veidekke Employee Share Trust) purchased 10 000 Veidekke shares at a price of NOK 102.30 each. The Trust now holds 216 573 shares. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

AppSpotr signs MoU with a Chinese company for restaurant apps

AppSpotr has, via the partly owned subsidiary AppSpotr Asia, signed a Memorandum of Understanding (MoU) with the Chinese company Mishu Technology (MST) to deliver apps to restaurants. The apps will be used for app based marketing, table reservations, ordering of takeout and mobile payments.As a first step, AppSpotr and MST will launch a joint pilot project to build and test the solution in up to 1 000 restaurants. After successful completion of pilot project, then AppSpotr will deliver apps to more restaurants. The exact costs associated with the development and selling of the app is

Interim Report 1 2017-05-01 – 2017-07-31

Mon, Sep 11, 2017 08:05 CET

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1.

Changes in Executive Management in Lundbeck

· Kåre Schultz has resigned from his position as President and CEO to join Teva Pharmaceutical Industries Ltd. as President and CEO · Coincidentally, Staffan Schüberg has also resigned from his position as Chief Commercial Officer to join a privately held company as CEO · The process of finding a replacement for Kåre Schultz and Staffan Schüberg will commence immediately and both will remain in their respective positions until further notice · The Board sees no reason for changes in the strategic direction of the company Valby, Denmark, 11 September 2017 - H. Lundbeck A/S (

IMFINZI superior PFS in Stage III lung cancer

11 September 2017 07:00 BST ASTRAZENECA PRESENTS SUPERIOR PROGRESSION-FREE SURVIVAL FOR IMFINZI IN THE PACIFIC TRIAL OF PATIENTS WITH LOCALLY-ADVANCED UNRESECTABLE LUNG CANCER AT ESMO 2017 CONGRESS Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting Data presented at the ESMO 2017 Congress follows FDA's recent Breakthrough Therapy Designation for Imfinzi in locally advanced, unresectable lung cancer The PACIFIC trial continues to evaluate the other primary endpoint,

Bonava acquires land and creates new homes in Bergen, Norway

Bonava has concluded an agreement for the acquisition of land from Tine SA at a price of approximately SEK 265 million. The property is situated in the Minde neighbourhood, with good transport links todgen city centre. Bonava will construct a total of approximately 300 housing units.- The acquisition is in line with our strategy to increase our market share in Bergen. Minde is an attractive area where we can play a part in continuing to develop happy neighbourhoods where people have the highest quality of life, says Joachim Hallengren, President and CEO of Bonava. The property is located

Mr Green launches predictive Green Gaming tool

Mr Green announced the launch today of its predictive Green Gaming tool. This unique tool gives players the ability to gain insight into their own risk behavior. At the same time, the tool’s functionality means Mr Green can better detect when healthy playing has moved into the risk zone. "It should feel safe to play at Mr Green, and Green Gaming has been a part of our business strategy since the foundation in 2007,” says Per Norman, CEO of Mr Green & Co. "We have high ambitions, and want to be the brand you associate with Green Gaming.” The new tool analyzes the

Tagrisso potential standard of care in lung cancer

11 September 2017 07:00 BST ASTRAZENECA'S TAGRISSO SHOWS POTENTIAL AS A NEW STANDARD OF CARE IN 1ST-LINE EGFR-MUTATED LUNG CANCER AT ESMO 2017 CONGRESS Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases Unprecedented median progression-free survival (PFS) of 18.9 months compared with 10.2 months for the current standard of care Clinically-meaningful preliminary overall survival benefit AstraZeneca has presented the full

Directorate Changes

11 September 2017 Genel Energy plc Directorate Changes Genel Energy plc ('Genel' or 'the Company') announces that Tim Bushell and Martin Gudgeon have been appointed as independent Non-Executive Directors of the Company with immediate effect. Mr Bushell is a qualified geologist with over 35 years' experience working in the oil and gas sector. He is currently on the Boards of Petro Matad, Rockhopper Exploration, and Point Resources. Previously, he spent a decade as CEO of Falkland Oil & Gas, was a co-founder of Core Energy, and was Managing Director of Paladin

Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C